Jessica is the managing director and chairman of Biotechnology Investment Banking at Morgan Stanley. During Jessica’s 30-year career of building Morgan Stanley’s biotechnology franchise, she has been responsible for $30 billion of capital raising and $65B of strategic transactions. In 2017, transactions include leading financings for Axovant, Biohaven, Editas, Galapagos, RegenxBio and Syndax, aggregating $1Bn in proceeds.  Previous strategic transactions include advising Cubist on its $9.5Bn sale to Merck, Pharmasset on its $11Bn sale to Gilead and Elan on its $8.6Bn sale to Perrigo. She has also been involved in the creation of a new asset class involving royalty-backed debt (PhaRMA) where over $16 billion has been raised.

Jessica has a BA in Commerce/Honours Economics from McGill University and an MBA from Harvard Business School.